Printer Friendly

/C O R E C T I O N -- Bradley Pharmaceuticals Earnings

        /C O R E C T I O N -- Bradley Pharmaceuticals Earnings/
    In NY050, moved March 11, Bradley Pharmaceuticals Earnings, we have


been informed by the company that the "Share loss" data for the "Quarter to Dec. 31, 1990" should have been "$(.17)," instead of "$(.04)," the "Weighted average shares outstanding" for the "Quartered to Dec. 31," was omitted, the figure for 1991 should have been "1,304,348" for 1990 "450,000." For the "Year to Dec. 31," "Share loss" for 1991 should have been, "$(.41)," instead of "$(.12)." "Share loss" for the "Year to Dec.
31, 1990" should have been, "$(1.38)" instead of "$(.29)."   "Weighted average shares outstanding" for 1991 should have been "665,342" instead of "2,175,000."
     "Weighted average shares outstanding" for 1990 should have been "450,000" instead of "2,175,000" as originally issued. The corrected version of the release follows.
               BRADLEY PHARMACEUTICALS REPORTS RESULTS
    FAIRFIELD, N.J., March 11 /PRNewswire/ -- Bradley Pharmaceuticals, Inc. (NASDAQ: BPRXA), reported today that sales for the fourth quarter ending December 1991 rose 76 percent to approximately $405,000 from the similar period in 1990.  Sales for the 12 months rose 38 percent to approximately $1,130,000.
    The sales increase in the fourth quarter was substantially due to the recent acquisition of Duadacin, a cold capsule from Hoechst-Roussel Pharmaceuticals Inc., and a good flu/cold season.
                     BRADLEY PHARMACEUTICALS, INC.
      Quarter to Dec. 31                 1991           1990
    Revenue                           $404,998       $230,074
    Net loss                          $(14,160)      $(78,585)
    Share loss                           $(.01)         $(.17)
    Weighted average
     shares outstanding              1,304,348        450,000
      Year to Dec. 31                    1991           1990
    Revenue                         $1,130,570       $816,346
    Net loss                         $(271,519)     $(622,404)
    Share loss                           $(.41)        $(1.38)
    Weighted average
     shares outstanding                665,342        450,000
    Bradley Pharmaceuticals, Inc., markets ethical prescription and non- prescription pharmaceuticals in five categories: hematinics, cough/cold, nutritionals, cardiovascular, and dermatology.  It acquires non- strategic products from major pharmaceutical companies and repositions and promotes them to a determined niche marketplace.
    Recently, the company expanded its operations by hiring additional sales persons and headquarters staff.
    -0-                      3/11/92
    /CONTACT:  Richard Audet, chief financial officer of Bradley Pharmaceuticals, 201-882-1505/
    (BPRXA) CO:  Bradley Pharmaceuticals, Inc. ST:  New Jersey IN:  MTC SU:  ERN SM -- NY069 -- 0220 03/20/92 16:31 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 20, 1992
Words:382
Previous Article:DOE AND U.S. COMPUTER COMPANIES AGREE ON MODEL FOR COOPERATIVE R&D
Next Article:GREAT WESTERN ACQUIRES AMERIFIRST FEDERAL SAVINGS BANK
Topics:


Related Articles
SPI PHARMACEUTICALS ANNOUNCES SECOND QUARTER DIVIDEND
IBM AND MULTI SOFT SIGN SOFTWARE MARKETING AGREEMENT
DCA ANNOUNCES SELECT COMM SERVER WITH PC ROUTER SUPPORT
IBM Ships OS/390 2.7, Previews Future Releases.
CAI to Help Make OS/390 Secure for E-Commerce.
A magical pair of 6x6 chemical squares.
PALMSOURCE JOINS KHRONOS GROUP.
Compuware Delivers Enhanced Enterprise Test Data Management Solution; Compuware File-AID/CS 3.0 Offers Rich Data-Management Functionality With...
Patients With HIV-Associated Wasting Gain More Weight With Concentrated Form of Megestrol Acetate, Study Shows.
Safety and efficacy of two preparations of megestrol acetate in HIV-infected individuals with weight loss in Africa, India, and the United States.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters